The Anterior Cutaneous Nerve Entrapment Syndrome (ACNES) 3.0 Randomized single-blind controlled trial of conservative treatment by local injection therapy (with or without corticosteroids) for entrapment of the anterior intercostal cutaneous nerve through the rectus abdominis muscle.

The Anterior Cutaneous Nerve Entrapment Syndrome (ACNES) 3.0 Randomized single-blind controlled trial of conservative treatment by local injection therapy (with or without corticosteroids) for entrapment of the anterior intercostal cutaneous nerve through the rectus abdominis muscle. - ACNES-Cortico

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON39921

Enrollment

136

Registered

2013-08-07

Start date

2013-08-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

buikwandpijnsyndroom The Anterior Cutaneous Nerve Entrapment Syndrome (ACNES). Chronic abdominal wall pain

Interventions

Group A: trigger point injection with10 cc lidocaine 2% combined with 40mg of corticosteroids 2-3 weeks after diagnosis and repeated once more 2-3 weeks later. Group B (control): trigger point inje

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -abdominal wall pain (ACNES) -unilateral -trigger point in musculus rectus -worse with Carnett's test -more than 50% pain reduction by local infiltration -informed consent -age over 18

Exclusion criteria

Exclusion criteria: -recent abdominal pathology -previous treatment for ACNES -allergic to lidocaine or methylprednisolonacetaat -no adequate follow up possible -blood analysis abnormalities not compatible with ACNES

Design outcomes

Secondary

Measure	Time frame
Pain levels 3 months after diagnosis and the necessity of other treatment for ACNES during this period	—

Primary

Measure	Time frame
Difference of number of patients with a more than 50% pain reduction on VAS and/or a 2 point reduction on the 5-point VRS 2-3 weeks after the second injection.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)